d, reflect a new reality: a third of the
new molecules in Lilly's development pipeline are not the traditional,
chemical ("small molecule") compounds, but rather "large molecule" drugs
synthesized from biological sources. Many other innovative companies are
investing in these molecules, as well. One of the key public policy
prescriptions he gave to better secure the state's biotech investment is
passage of a bill that would ensure that intellectual property and data
around biologics are appropriately protected. That legislation, the
"Pathway for Biosimilars Act" (H.R. 5629), is now before Congress and is
sponsored by several members of Massachusetts congressional delegation,
including Reps. Michael Capuano, William Delahunt, Stephen F. Lynch and
James P. McGovern. Without such protections, Lechleiter said, "the
rationale for such investment will simply collapse in many cases."
He further called on policymakers to support fixing the country's
immigration system to allow top-notch talent to come to the U.S. to foster
innovation and research. And he stressed the importance of transparency on
the part of regulators in setting their expectations and requirements of
drug developers.
The Biz/Bio Program was established in 2004 to build "bridges of
understanding" between key sectors - from government and financial
interests to academic and pharmaceutical/biotech leaders - to establish and
maintain a healthy environment for building and sustaining local and
regional bioscience clusters.
The full text of Lechleiter's speech can be obtained at http://www.lilly.com.
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provide
'/>"/>
SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation2.
Lilly Declares Fourth-Quarter Dividend3.
Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar4.
Lilly and BioMS Medical Announce Global Licensing and Development Agreement5.
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration6.
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:7.
Lilly Announces Termination of AIR Insulin Program8.
HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership9.
Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education10.
Lilly Reports Solid First-Quarter Results11.
Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing